5 comments, add yours

Thoughts on Geraldine Ferraro, and Myeloma

Like many New Yorkers, fem­i­nists?, hema­tol­o­gists and other people, I was sad­dened to learn yes­terday of Geraldine Ferraro’s death. The Depression-​​era born mother, attorney, criminal pros­e­cutor, Con­gress­woman, 1984 Demo­c­ratic VP-​​candidate and part-​​time neighbor to yours truly, suc­cumbed to com­pli­ca­tions of mul­tiple myeloma at the age of 75.

Abnormal plasma cells in a bone marrow sample said to be from a patient with myeloma (Wiki­media Commons). Plasma cells have nearly-​​round, eccentric nuclei and abundant cyto­plasm (ES).

Myeloma is a cancer of plasma cells — spe­cialized white blood cells (mature B lym­pho­cytes) that make anti­bodies. Plasma cells nor­mally develop in the bone marrow; they can exit into the blood­stream, which is why this con­dition is often called a tumor of the bone marrow or, occa­sionally, some­times, as a leukemia. The term myeloma comes from Greek roots – muelo (which can refer to the bone marrow) and -oma, which in medical par­lance has come to stand for a tumor and may derive from soma (body).

According to the NCI, over 20,000 North Amer­icans receive a myeloma diag­nosis, and approx­i­mately 10,000 die from the dis­order each year. It tends to arise in older folks, and is slightly more prevalent in men than in women. According to the SEER data, in 2007 there were over 61,000 men and women in the U.S. alive with a history of this disease.

What’s notable to me, as a hema­tol­ogist, about the former con­gress­woman is that she lived with myeloma for over 12 years: She sur­vived with a disease for which there were few treat­ments available when she was on the Pres­i­dential ticket. This was partly due to luck – always a factor in cancer out­comes, as some cases are intrin­si­cally more aggressive than others; partly due to her access to excellent doctors and good care; and, also, likely due to advances in myeloma treatment over the past two decades.

Some per­spective: When I com­pleted my fel­lowship in 1993, the median sur­vival for someone with myeloma was less than 3 years. Starting around then, most spe­cialists steered patients under the age of 65, and in some com­mu­nities, older patients as well, toward autol­ogous stem cell trans­plan­tation — an aggressive approach that’s been shown to prolong lives of patients in ran­domized studies. (For the record, I’ve never been con­vinced by those data.) More recently, old drugs like thalidomide and its fresher deriv­ative, lenalidomide (Revlimid), along with new drugs like borte­zomib (Velcade) have demon­strated efficacy in this disease.

In my opinion, what’s ahead for doctors caring for myeloma patients — and for the patients, even more so — in this next decade, is to see if these old and new pills might be better, less costly and less toxic than transplant-​​based treatment regimens.

A final thought on Ferraro’s care, is that it seems she ben­e­fited from the care of experts: hematologist-​​oncologists, trans­plant physi­cians and other spe­cialists and sub­spe­cialists. With all the push now for more primary care doctors — who are indeed needed — her sur­vival with what might have been a quickly ter­minal illness is a tes­tament to the value of knowl­edgeable, well-​​trained physi­cians who keep up with devel­op­ments in an evolving field.

As for the ceiling-​​breaking con­gress­woman, my thoughts are with her family now. She was a remarkable lady in many ways.

(all links accessed 3/​27/​11)

Related Posts:

5 comments to Thoughts on Geraldine Ferraro, and Myeloma

Leave a Reply